Current FDA guidance does not recommend routine calcitonin monitoring in patients using GLP-1 medications unless they have specific risk factors
Some patients may experience mild fatigue or low energy , especially when starting treatment
Key facts about GLP-1-related gastroparesis: How it happens: GLP-1 drugs slow gastric emptying as part of their mechanism, but this effect becomes excessive in some people Whos at risk: Those with pre-existing digestive disorders, prior gastric surgery, long-standing diabetes, or elderly patients face higher risk Timeline: Symptoms can appear at any point during treatment, especially during dose increases Reversibility: Most cases improve after dose reduction or medication discontinuation, with recovery taking days to several months Management options: Dietary changes (smaller, low-fat meals), slower dose escalation, supportive medications, or temporary drug cessation Seek immediate medical attention for severe vomiting, dehydration signs, intense abdominal pain, or blood in vomit or stool
Gastroenterology 2002;122:531-44.ArticlePubMed 10